Ezhou

Researchers are investigating the effectiveness and safety of a sublingual immunotherapy called MM09 for treating people aged 12 to 65 with moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites (Dermatophagoides pteronyssinus and/or Dermatophagoides farinae). The study also includes participants with or without mild-to-moderate controlled asthma. This phase III, randomized, double-blind, placebo-controlled trial aims to see if MM09 can reduce symptoms and the need for rescue medication compared to a placebo. Participants receive a sublingual spray of MM09 at a dose of 30,000 TU/mL or a placebo for 12 months. The treatment is given daily under the tongue. The trial is conducted at multiple centers and includes careful monitoring of participants throughout the treatment period. Researchers will observe participants for any medical problems that occur when inhaling MM09 and compare results with those receiving the placebo. During the study, participants will use a smartphone to record their symptoms and medication use. Researchers will assess the combined symptom and medication score during the last four weeks of treatment to evaluate effectiveness. Safety assessments and monitoring for adverse effects will also be conducted. The total duration of participation includes the 12-month treatment period with ongoing evaluations to understand MM09's impact on allergic rhinitis, rhinoconjunctivitis, and asthma symptoms.